TranS1 Inc.  

(Public, NASDAQ:TSON)   Watch this stock  
Find more results for TSON
1.91
+0.11 (6.11%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.82 - 2.00
52 week 1.55 - 3.40
Open 1.82
Vol / Avg. 82,754.00/46,575.00
Mkt cap 52.18M
P/E     -
Div/yield     -
EPS -1.10
Shares 27.32M
Beta 0.63
Inst. own 63%
Aug 5, 2013
Q2 2013 TRANS1 INC Earnings Release Add to calendar
May 9, 2013
Q1 2013 TRANS1 INC Earnings Conference Call
May 6, 2013
Q1 2013 TRANS1 INC Earnings Release
Mar 19, 2013
TRANS1 INC at Canaccord Genuity Musculoskeletal Conference
Mar 6, 2013
TRANS1 INC at Cowen Health Care Conference
Mar 4, 2013
TRANS1 INC Conference Call to Discuss Q4 2012 Earnings and Acquisition of Baxano, Inc
Feb 28, 2013
TRANS1 INC at Lazard Medical Technology Snowbird Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -289.95% -205.13%
Operating margin -289.92% -204.12%
EBITD margin - -139.16%
Return on average assets -138.37% -69.27%
Return on average equity -178.33% -84.62%
Employees 89 -
Carbon Disclosure Rating - -

Address

301 GOVERNMENT CENTER DRIVE
WILMINGTON, NC 28403
United States - Map
+1-910-3321700 (Phone)
+1-910-3321701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

TranS1 Inc. (TranS1) is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region. It develops its pre-sacral approach to allow spine surgeons to access and treat intervertebral spaces without compromising important surrounding soft tissue, nerves and bone structures. As of December 31, 2011, the Company was marketing the AxiaLIF family of products for single and multilevel lumbar fusion, the Vectre and Avatar lumbar posterior fixation systems and Bi-Ostetic bone void filler, a biologics product. All of the Company�s AxiaLIF products are delivered using its pre-sacral approach. It generates revenue from the sales of itsimplants and disposable surgical instruments. In November 2011, the Company launched its VEO Lateral Access and Interbody Fusion System.

Officers and directors

Paul A. LaViolette Independent Chairman of the Board
Bio & Compensation  - Reuters
Ken Reali President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Joseph P. Slattery Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Rick Feiler Vice President - Marketing
Age: 52
Bio & Compensation  - Reuters
Stephanie M. Fitts Ph.D. Vice President - Regulatory, Quality and Compliance
Bio & Compensation  - Reuters
Stephen D. Ainsworth Ph.D. Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Mukesh Ramchandani Vice President - Business and Market Development
Age: 46
Bio & Compensation  - Reuters
Mark T. Stautberg Director
Age: 53
Bio & Compensation  - Reuters
Michael A Carusi Independent Director
Age: 47
Bio & Compensation  - Reuters
Jeffrey Fischgrund M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters